Regeneron to buy 23andMe out of bankruptcy for $256 million
The company filed for Chapter 11 bankruptcy protection in March 2025 [File] | Photo Credit: AP Regeneron Pharmaceuticals said Monday it will buy genetic testing company 23andMe out of bankruptcy for $256 million, a deal that provides the U.S. biotech company with data on millions of clients. New York-based Regeneron said it had been named […]
Continue Reading
